CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Core Viewpoint - CytoSorbents Corporation will report its fourth quarter and full year 2024 financial results on March 6, 2025, highlighting its advancements in blood purification technologies for critical care [1][2]. Company Overview - CytoSorbents Corporation specializes in treating life-threatening conditions in intensive care and cardiac surgery through blood purification technologies [4]. - The company's proprietary technologies utilize biocompatible, highly porous polymer beads to remove toxic substances from blood and bodily fluids [4]. - CytoSorbents' lead product, CytoSorb, is approved in the European Union and distributed in 76 countries, with over 250,000 devices used to date [5]. Product Development - The company is developing the DrugSorb™-ATR antithrombotic removal system to mitigate perioperative bleeding in high-risk surgeries [6]. - DrugSorb-ATR has received two FDA Breakthrough Device Designations for removing specific blood thinners during urgent cardiothoracic procedures [6]. - The company submitted a De Novo medical device application to the U.S. FDA for DrugSorb-ATR, which is currently under substantive review [6]. Market Presence - CytoSorb has received FDA Emergency Use Authorization for critically ill COVID-19 patients, although it is not yet approved in the U.S. [5]. - The company holds numerous patents and trademarks for its blood purification technologies, with several products under development [7].